Report Sections

See All Reports

  • HP:0007018: Attention deficit hyperactivity disorder
  • Pneumonia (361) Abnormality of the cardiovascular system (36) Respiratory tract infection (36) Neoplasm (29) Hypoxemia (28) Diabetes mellitus (25) Depressivity (24) Thromboembolism (23) Acute kidney injury (22) Abnormal lung morphology (21) Anosmia (19) Hypertension (18) Abnormality of coagulation (15) Pulmonary embolism (15) Pulmonary fibrosis (15) Stroke (14) Arthritis (14) Interstitial pneumonitis (14) Myocardial infarction (12) Type II diabetes mellitus (12) Deep venous thrombosis (11) Rheumatoid arthritis (10) Leukemia (10) Respiratory distress (10) Low levels of vitamin D (10) Behavioral abnormality (9) Mental deterioration (9) Chronic pain (9) Congestive heart failure (8) Myocarditis (8) Type I diabetes mellitus (8) Sepsis (8) Infertility (7) Abnormality of the liver (7) Lymphopenia (7) Inflammation of the large intestine (7) Pulmonary obstruction (7) Pulmonary insufficiency (7) Immunodeficiency (6) Systemic lupus erythematosus (6) Chronic pulmonary obstruction (6) Abnormality of the gastrointestinal tract (6) Neoplasm of the lung (6) Encephalopathy (5) Obesity (5) Lymphoma (5) Autoimmunity (5) Breast carcinoma (5) Disseminated intravascular coagulation (5) Fatigue (5) Abnormality of the kidney (4) Coronary artery atherosclerosis (4) Cardiac arrest (4) Headache (4) Colon cancer (4) Arrhythmia (4) Carcinoma (4) Hypercoagulability (4) Autistic behavior (3) Seizure (3) Cardiomyopathy (3) Dysphagia (3) Migraine (3) Pulmonary arterial hypertension (3) Asthma (3) Bronchiectasis (3) Neoplasm of the pancreas (3) Psoriasiform dermatitis (3) Attention deficit hyperactivity disorder (3) Cutaneous melanoma (3) Neoplasm of head and neck (3) Pulmonary edema (3) Insomnia (3) Neoplasm of the large intestine (3) Renal insufficiency (2) Hypogeusia (2) Hearing impairment (2) Abnormality of the eye (2) Visual impairment (2) Conjunctivitis (2) Psychosis (2) Autism (2) Dementia (2) Abnormality of the endocrine system (2) Abnormality of the thyroid gland (2) Jaundice (2) Hepatic fibrosis (2) Premature birth (2) Abnormal heart morphology (2) Abnormality of blood and blood-forming tissues (2) Fever (2) Diarrhea (2) Hypothermia (2) Neurodegeneration (2) Abnormal intestine morphology (2) Alopecia of scalp (2) Encephalitis (2) Obstructive sleep apnea (2) Male infertility (2) Stillbirth (2) Paroxysmal atrial fibrillation (2) Lymphoid leukemia (2) Myeloproliferative disorder (2) Chronic lymphatic leukemia (2) Renal cell carcinoma (2) Multiple myeloma (2) Abnormal anterior horn cell morphology (2) Amyotrophic lateral sclerosis (2) Sleep apnea (2) Cystoid macular edema (2) Hemeralopia (2) Arteritis (2) Chronic kidney disease (2) Cervix cancer (2) Cholangitis (2) Cholangiocarcinoma (2) Myositis (2) Neuroendocrine neoplasm (2) Neoplasm of the rectum (2) Mania (2) Nephritis (1) Menorrhagia (1) Conductive hearing impairment (1) Cataract (1) Amblyopia (1) Periodontitis (1) Abnormality of the nervous system (1) Oligospermia (1) Adrenal insufficiency (1) Hyperaldosteronism (1) Abnormality of the skin (1) Lymphedema (1) Cholecystitis (1) Keratoconjunctivitis (1) Intellectual disability (1) Spastic diplegia (1) Hemiparesis (1) Meningitis (1) Cerebral hemorrhage (1) Abnormal joint morphology (1) Hepatic failure (1) Hepatocellular carcinoma (1) Intrauterine growth retardation (1) Hoarse voice (1) Dysphonia (1) Weak voice (1) Sudden cardiac death (1) Cor pulmonale (1) Tachycardia (1) Aortic valve stenosis (1) Bradycardia (1) Torsade de pointes (1) Atrioventricular block (1) Angina pectoris (1) Pancreatitis (1) Premature rupture of membranes (1) Weight loss (1) Thrombocytopenia (1) Autoimmune thrombocytopenia (1) Gastroesophageal reflux (1) Anorexia (1) Esophageal varix (1) Apnea (1) Status epilepticus (1) Subarachnoid hemorrhage (1) Memory impairment (1) Difficulty walking (1) Hyperkinetic movements (1) Alzheimer disease (1) Increased intracranial pressure (1) Colitis (1) Biliary cirrhosis (1) Hypotension (1) Vascular dilatation (1) Atherosclerosis (1) Osteoarthritis (1) Tachypnea (1) Hypoventilation (1) Myelodysplasia (1) Neoplasm of the liver (1) Hypokalemia (1) Hyponatremia (1) Hyperphosphatemia (1) Reduced factor VIII activity (1) Skeletal muscle atrophy (1) Myalgia (1) Muscular dystrophy (1) Neonatal death (1) Increased body weight (1) Neoplasm of the nervous system (1) Malnutrition (1) Thrombophlebitis (1) Ventricular tachycardia (1) Acute myeloid leukemia (1) Dilatation of the cerebral artery (1) Knee osteoarthritis (1) Monoclonal immunoglobulin M proteinemia (1) Intraalveolar phospholipid accumulation (1) Neoplasm of the stomach (1) Neoplasm of the genitourinary tract (1) Neoplasm of the skin (1) Female infertility (1) Benign prostatic hyperplasia (1) Hip osteoarthritis (1) Renal neoplasm (1) Uterine neoplasm (1) Testicular neoplasm (1) Intestinal atresia (1) Tonsillitis (1) Inflammatory abnormality of the skin (1) Placental abruption (1) Postprandial hyperglycemia (1) Endometrial carcinoma (1) Erythroid hypoplasia (1) Asterixis (1) Glioblastoma multiforme (1) B-cell lymphoma (1) Ciliary dyskinesia (1) Morphea (1) Allergy (1) Non-Hodgkin lymphoma (1) Retinal vein occlusion (1) Heart block (1) Dyspareunia (1) Ductal carcinoma in situ (1) Endometriosis (1) Cardiogenic shock (1) Vulvar neoplasm (1) Addictive behavior (1) Femur fracture (1) Neonatal sepsis (1) Glue ear (1) Neoplasm of the central nervous system (1) Abnormality of movement (1) Ulcerative colitis (1) Crohn's disease (1) Endocarditis (1) Toxemia of pregnancy (1) Neoplasm of the larynx (1) Ovarian neoplasm (1) Vaginal neoplasm (1) Cellulitis (1) Bulimia (1) Atelectasis (1) Esophageal neoplasm (1) Lymphocytosis (1) Polymenorrhea (1)

    HP:0007018: Attention deficit hyperactivity disorder

    Developed by Shray Alag, The Harker School
    Sections: Correlations, Clinical Trials, and HPO

    Correlations computed by analyzing all clinical trials.

    Navigate: Clinical Trials and HPO


    Correlated Drug Terms (8)


    Name (Synonyms) Correlation
    drug3320 The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care: Wiki 0.58
    drug2341 PLACEBO GROUP Wiki 0.58
    drug1672 Interview by psychologists Wiki 0.58
    Name (Synonyms) Correlation
    drug544 CD24Fc Wiki 0.58
    drug549 CHLORPROMAZINE (CPZ) Wiki 0.58
    drug357 BCG GROUP Wiki 0.58
    drug3140 Standard of Care (SOC) Wiki 0.26
    drug2448 Placebo Wiki 0.03

    Correlated MeSH Terms (24)


    Name (Synonyms) Correlation
    D001289 Attention Deficit Disorder with Hyperactivity NIH 1.00
    D000067877 Autism Spectrum Disorder NIH 0.58
    D009080 Mucocutaneous Lymph Node Syndrome NIH 0.58
    Name (Synonyms) Correlation
    D001997 Bronchopulmonary Dysplasia NIH 0.58
    D008595 Menorrhagia NIH 0.58
    D006948 Hyperkinesis NIH 0.58
    D006929 Hyperaldosteronism NIH 0.58
    D014552 Urinary Tract Infections NIH 0.58
    D054559 Hyperphosphatemia NIH 0.58
    D004314 Down Syndrome NIH 0.58
    D000309 Adrenal Insufficiency NIH 0.58
    D007008 Hypokalemia NIH 0.58
    D002659 Child Development Disorders, Pervasive NIH 0.41
    D004194 Disease NIH 0.35
    D001321 Autistic Disorder NIH 0.33
    D006470 Hemorrhage NIH 0.33
    D020141 Hemostatic Disorders NIH 0.15
    D001778 Blood Coagulation Disorders NIH 0.15
    D006973 Hypertension NIH 0.14
    D013577 Syndrome NIH 0.06
    D003141 Communicable Diseases NIH 0.04
    D007239 Infection NIH 0.03
    D045169 Severe Acute Respiratory Syndrome NIH 0.02
    D018352 Coronavirus Infections NIH 0.02

    Correlated HPO Terms (10)


    Name (Synonyms) Correlation
    HP:0000729 Autistic behavior HPO 0.67
    HP:0002905 Hyperphosphatemia HPO 0.58
    HP:0002900 Hypokalemia HPO 0.58
    Name (Synonyms) Correlation
    HP:0000846 Adrenal insufficiency HPO 0.58
    HP:0002487 Hyperkinetic movements HPO 0.58
    HP:0000132 Menorrhagia HPO 0.58
    HP:0000859 Hyperaldosteronism HPO 0.58
    HP:0000717 Autism HPO 0.41
    HP:0001928 Abnormality of coagulation HPO 0.15
    HP:0000822 Hypertension HPO 0.14

    Clinical Trials

    Navigate: Correlations   HPO

    There are 3 clinical trials


    1 Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs

    The study investigators are interested in learning more about how drugs, that are given to children by their health care provider, act in the bodies of children and young adults in hopes to find the most safe and effective dose for children. The primary objective of this study is to evaluate the PK of understudied drugs currently being administered to children per SOC as prescribed by their treating provider.

    NCT04278404
    Conditions
    1. Coronavirus Infection (COVID-19)
    2. Pulmonary Arterial Hypertension
    3. Urinary Tract Infections in Children
    4. Hypertension
    5. Pain
    6. Hyperphosphatemia
    7. Primary Hyperaldosteronism
    8. Edema
    9. Hypokalemia
    10. Heart Failure
    11. Hemophilia
    12. Menorrhagia
    13. Insomnia
    14. Pneumonia
    15. Skin Infection
    16. Arrythmia
    17. Asthma in Children
    18. Bronchopulmonary Dysplasia
    19. Adrenal Insufficiency
    20. Fibrinolysis; Hemorrhage
    21. Attention Deficit Hyperactivity Disorder
    22. Multisystem Inflammatory Syndrome in Children (MIS-C)
    23. Kawasaki Disease
    24. Coagulation Disorder
    25. Down Syndrome
    Interventions
    1. Drug: The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:
    MeSH:Infection Communicable Diseases Urinary Tract Infections Coronavirus Infections Severe Acute Respiratory Syndrome Bronchopulmonary Dysplasia Down Syndrome Menorrhagia Hypertension Hemostatic Disorders Mucocutaneous Lymph Node Syndrome Blood Coagulation Disorders Hyperphosphatemia Hypokalemia Adrenal Insufficiency Hyperaldosteronism Disease Syndrome Hemorrhage Attention Deficit Disorder with Hyperactivity
    HPO:Abnormality of coagulation Abnormality of the coagulation cascade Adrenal insufficiency Attention deficit hyperactivity disorder Hyperaldosteronism Hyperphosphatemia Hypertension Hypokalemia Menorrhagia Primary hyperaldosteronism

    Primary Outcomes

    Measure: Clearance (CL) or apparent oral clearance (CL/F) as measured by PK sampling

    Time: Data will be collected up to 90 days from the time of consent. For participants with Down Syndrome enrolling at sites designated as Down Syndrome sites, participants will be in the study for up to 210 days.

    Measure: Volume of distribution (V) or apparent oral volume of distribution (V/F) as measured by PK sampling

    Time: Data will be collected up to 90 days from the time of consent. For participants with Down Syndrome enrolling at sites designated as Down Syndrome sites, participants will be in the study for up to 210 days.

    Measure: Elimination rate constant (ke) as measured by PK sampling

    Time: Data will be collected up to 90 days from the time of consent. For participants with Down Syndrome enrolling at sites designated as Down Syndrome sites, participants will be in the study for up to 210 days.

    Measure: Half-life (t1/2) as measured by PK sampling

    Time: Data will be collected up to 90 days from the time of consent. For participants with Down Syndrome enrolling at sites designated as Down Syndrome sites, participants will be in the study for up to 210 days.

    Measure: Absorption rate constant (ka) as measured by PK sampling

    Time: Data will be collected up to 90 days from the time of consent. For participants with Down Syndrome enrolling at sites designated as Down Syndrome sites, participants will be in the study for up to 210 days.

    Measure: AUC (area under the curve) as measured by PK sampling

    Time: Data will be collected up to 90 days from the time of consent. For participants with Down Syndrome enrolling at sites designated as Down Syndrome sites, participants will be in the study for up to 210 days.

    Measure: Maximum concentration (Cmax) as measured by PK sampling

    Time: Data will be collected up to 90 days from the time of consent. For participants with Down Syndrome enrolling at sites designated as Down Syndrome sites, participants will be in the study for up to 210 days.

    Measure: Time to achieve maximum concentration (Tmax) as measured by PK sampling

    Time: Data will be collected up to 90 days from the time of consent. For participants with Down Syndrome enrolling at sites designated as Down Syndrome sites, participants will be in the study for up to 210 days.
    2 Clinical Evolution and Parenting in Children and Adolescents With Autism Spectrum Disorder or Attention Deficit Hyperactivity Disorder Quarantined Because of Covid-19 Outbreak

    In response to the coronavirus disease 2019 (covid-19) outbreak, the home confinement of the population ordered by governments in many countries raise questions about its impact on individuals' physical and mental health in the short and longer term. In children, reduced physical activity, changes in lifestyle, disturbances in sleep patterns, lack of in-person contact with peers, poor or inadequate understanding of health risks may be risk factors of anxiety, stress, fatigue, sleep disorders (Brooks et al, 2020; Wang et al, 2020; Sprang et al, 2013). These problematic effects could be modulated by social factors (housing in urban or rural areas, availability of personal space at home, parenting stress, etc.) (Cluver et al, 2020; Liu et al, 2020).

    NCT04416360
    Conditions
    1. Autism Spectrum Disorder
    2. Attention-deficit Hyperactivity Disorder
    Interventions
    1. Other: Interview by psychologists
    MeSH:Hyperkinesis Disease Autistic Disorder Attention Deficit Disorder with Hyperactivity Autism Spectrum Disorder Child Development Disorders, Pervasive
    HPO:Attention deficit hyperactivity disorder Autism Autistic behavior Hyperactivity Hyperkinetic movements

    Primary Outcomes

    Description: composition, home confinement, change in the environment, personal room at home, screens with internet access, parents' current professional status, teleworking, care, family concerns related to Covid-19, parenting stress, schooling, recurrent complaints.

    Measure: Interview of the parents : contextual data

    Time: Baseline

    Description: related to education; related to daily family life; related to leisure, related to care (children/adolescents, parents)

    Measure: Interview of the children/adolescents/ parents : Experience of the confinement in general

    Time: Baseline

    Description: related to education; related to daily family life; related to leisure, related to care (children/adolescents, parents)

    Measure: Interview of the children/adolescents/ parents : Experience of the confinement in general

    Time: 1 month

    Description: related to education; related to daily family life; related to leisure, related to care (children/adolescents, parents)

    Measure: Interview of the children/adolescents/ parents : Experience of the confinement in general

    Time: 3 months

    Description: Data relating to disease and management of care. Experience of the referring caregiver.

    Measure: Interview of the referring caregiver : data relating to disease and management of care

    Time: 3 months
    3 Brain Imaging and Infant Development

    The aims of the BIBS Study The Brain Imaging in Babies study (BIBS) aims to improve understanding of how a baby's brain develops from before birth, up until 3-4 years of age. Working with children from a variety of backgrounds and communities, the investigators use a combination of state-of-the-art diagnostic tools such as MRI scans alongside traditional behavioural assessments to capture the earliest information on infant brain development. The focus of the BIBS study MRI scanning is a safe way of producing detailed images using strong magnetic fields and radio waves. It does not use X-ray. Along with learning more about brain development in general, the investigators also try to identify features that may in future help predict whether a child will or will not develop traits of conditions such as Autism Spectrum Disorder (ASD) or Attention Deficit Hyperactivity Disorder (ADHD). Long-term, this may help target useful interventions early on, helping children who are most in need. Since COVID-19 arrived in the United Kingdom (U.K.) in 2020, the investigators have been given ethical approval to include testing for this infection in the mothers and children participating in the study. This may provide an opportunity to better understand how mother and baby respond to infections. The investigators particularly welcome mothers who have had a positive COVID-19 test during their pregnancy to join the study.

    NCT04443179
    Conditions
    1. Autism Spectrum Disorder
    2. Attention Deficit Hyperactivity Disorder
    3. Neurodevelopmental Conditions
    4. COVID-19
    MeSH:Disease Attention Deficit Disorder with Hyperactivity Autism Spectrum Disorder
    HPO:Attention deficit hyperactivity disorder Autistic behavior

    Primary Outcomes

    Measure: Neurodevelopmental Outcomes

    Time: 3-4 years of age

    HPO Nodes


    HP:0007018: Attention deficit hyperactivity disorder
    Genes 387
    TGIF1 SH2B1 EEF1A2 GNE TBL1X ALG13 HSPG2 NODAL GNE POLA1 AGTR2 ZNF711 GTF2IRD1 SLC9A7 NECAP1 PHF21A FRMPD4 CNKSR2 SATB2 KIF11 SHH GABRG2 ARVCF SLITRK1 SETD5 MED13 YY1 RREB1 GNB5 TRAPPC14 STXBP1 ARX AARS1 PIEZO2 FGF8 DMD RAB39B GAS1 TGFBR2 FOXH1 CLIP2 ELN GRIN2A FANCD2 MYT1L HIRA GP1BB SVBP ACTL6B ADNP DLL1 SEC24C SIX3 CDK8 TIMM8A GABRG2 ELN PIK3CA HCN1 PAH CLTC SATB2 TLK2 WAC PMS2 FOXH1 CLCN4 GABRA5 GABRG2 CDON TSC1 GDI1 SLC1A2 PTCHD1 GAS1 HDC GABRB2 NPAP1 KRAS JRK NTRK2 CDON CDK19 KMT2E IGF2 SHH DISP1 ASPM TANC2 STS ZIC2 ACTL6B SNORD115-1 LIG4 GALC MADD NF1 DISP1 FGD1 KCNB1 MKRN3-AS1 FOXH1 TSPAN7 YWHAG SEMA3E TDGF1 IKBKG DHTKD1 FAN1 TKT FTSJ1 MED13 GLI2 FGF8 ABCD1 YWHAG PPM1D CNKSR2 GRIA4 FGFR1 IGF1 ZNF81 TAF1 KMT2A PWRN1 IPW HOXA2 CHRNA7 FLI1 PAK3 SNRPN DISP1 DALRD3 TRIO STAG2 ARID2 KCNA2 SIX3 RAI1 SH2B1 MED12 NKAP MSH6 ZIC2 WDFY3 KIF14 CACNA1H GABRA2 MSH2 DHCR7 FGF8 SHH SYNGAP1 DYM RIC1 NOP56 FGFR3 NODAL AP3B2 DDX6 PTCH1 ZIC2 RAD21 NUS1 SOX5 KANSL1 DLL1 RERE SLC6A8 FGF12 DNM1 ODC1 KAT8 BCORL1 MAGEL2 ACSL4 PCNT TET3 STS CLTC CDON SPRED1 MID2 CDKN1C STAG2 PPP1R12A SLC13A5 FBXW11 PTCH1 GLI2 ANAPC1 PWAR1 WAC SCN8A SLC2A1 THRB CNKSR2 TSC2 GLUD1 MAPK1 CARS1 IFNG NIPBL USP9X MKRN3 PANK2 FGFR1 DLL1 NSUN2 RAI1 TCF20 OPHN1 PCGF2 DYRK1A RPS20 FMR1 MED12 CSGALNACT1 IL1RAPL1 APC2 ODC1 CACNA1A TBX1 NSD1 JMJD1C C12ORF4 TBX1 EPCAM MECP2 TBL2 SIM1 TBX1 WWOX SYNJ1 METTL5 DNAJC12 PRNP TUBB2B CSNK2A1 FOXP1 RFC2 TMCO1 GATA4 SNORD116-1 LIMK1 MED12 MYT1L CRBN SIX3 PTCHD1 ATP6V1A GLI2 SMPD1 ARV1 CRKL PMS1 SZT2 MCTP2 BPTF SIN3A SYP CDON ZMIZ1 TBX1 ZNF41 STEEP1 IQSEC2 CACNA1B CIC GABRB3 ACTL6A DEAF1 ZIC2 PSMD12 SCN8A MLH1 GABRA1 FOXH1 USP27X FGD1 TSC2 PHIP GRIN2D FGF8 SNRPN NDP NBN PRKCG TANC2 TGIF1 NLGN1 WAC UBE3A ZMIZ1 SMC1A HDAC4 TDGF1 TSC1 HMGA2 PTCH1 IQSEC1 GLI2 SEMA4A GAS1 PPP3CA GAS1 DOCK3 UFD1 TGIF1 SH3KBP1 PLAG1 GTF2I KDM3B GNAQ CYFIP2 KCNA2 KANSL1 GRIN2A PTCH1 NR2F1 TRAK1 UBA5 SETD5 TDGF1 RAI1 MED12L PARS2 TGIF1 BMPR1A CHD7 ARF1 UPF3B ALKBH8 SMC1A CDH2 NDN SETD2 UPF3B OCRL DHDDS HCFC1 SMC3 TDGF1 ZDHHC9 DLL1 TRMT1 SHH DPH1 SIX3 RERE TKT HDAC8 MLH3 HERC2 SRPX2 STAG2 DLG3 DRD5 MLXIPL MAP1B IQSEC2 BCR RSRC1 SETBP1 SPG7 SCN3A LHCGR BCORL1 NODAL BAZ1B DLL1 TRAPPC4 MED12 COMT USP7 DRD4 FLII NTNG1 ARHGEF6 DYNC1I2 NODAL RPS6KA3 AUTS2 RLIM TRIO PAH DISP1
    Protein Mutations 2
    D203E G143E

    HPO

    Alphabetical listing of all HPO terms. Navigate: Correlations   Clinical Trials


    HPO Nodes


    HP:0007018: Attention deficit hyperactivity disorder
    Genes 387
    TGIF1 SH2B1 EEF1A2 GNE TBL1X ALG13 HSPG2 NODAL GNE POLA1 AGTR2 ZNF711 GTF2IRD1 SLC9A7 NECAP1 PHF21A FRMPD4 CNKSR2 SATB2 KIF11 SHH GABRG2 ARVCF SLITRK1 SETD5 MED13 YY1 RREB1 GNB5 TRAPPC14 STXBP1 ARX AARS1 PIEZO2 FGF8 DMD RAB39B GAS1 TGFBR2 FOXH1 CLIP2 ELN GRIN2A FANCD2 MYT1L HIRA GP1BB SVBP ACTL6B ADNP DLL1 SEC24C SIX3 CDK8 TIMM8A GABRG2 ELN PIK3CA HCN1 PAH CLTC SATB2 TLK2 WAC PMS2 FOXH1 CLCN4 GABRA5 GABRG2 CDON TSC1 GDI1 SLC1A2 PTCHD1 GAS1 HDC GABRB2 NPAP1 KRAS JRK NTRK2 CDON CDK19 KMT2E IGF2 SHH DISP1 ASPM TANC2 STS ZIC2 ACTL6B SNORD115-1 LIG4 GALC MADD NF1 DISP1 FGD1 KCNB1 MKRN3-AS1 FOXH1 TSPAN7 YWHAG SEMA3E TDGF1 IKBKG DHTKD1 FAN1 TKT FTSJ1 MED13 GLI2 FGF8 ABCD1 YWHAG PPM1D CNKSR2 GRIA4 FGFR1 IGF1 ZNF81 TAF1 KMT2A PWRN1 IPW HOXA2 CHRNA7 FLI1 PAK3 SNRPN DISP1 DALRD3 TRIO STAG2 ARID2 KCNA2 SIX3 RAI1 SH2B1 MED12 NKAP MSH6 ZIC2 WDFY3 KIF14 CACNA1H GABRA2 MSH2 DHCR7 FGF8 SHH SYNGAP1 DYM RIC1 NOP56 FGFR3 NODAL AP3B2 DDX6 PTCH1 ZIC2 RAD21 NUS1 SOX5 KANSL1 DLL1 RERE SLC6A8 FGF12 DNM1 ODC1 KAT8 BCORL1 MAGEL2 ACSL4 PCNT TET3 STS CLTC CDON SPRED1 MID2 CDKN1C STAG2 PPP1R12A SLC13A5 FBXW11 PTCH1 GLI2 ANAPC1 PWAR1 WAC SCN8A SLC2A1 THRB CNKSR2 TSC2 GLUD1 MAPK1 CARS1 IFNG NIPBL USP9X MKRN3 PANK2 FGFR1 DLL1 NSUN2 RAI1 TCF20 OPHN1 PCGF2 DYRK1A RPS20 FMR1 MED12 CSGALNACT1 IL1RAPL1 APC2 ODC1 CACNA1A TBX1 NSD1 JMJD1C C12ORF4 TBX1 EPCAM MECP2 TBL2 SIM1 TBX1 WWOX SYNJ1 METTL5 DNAJC12 PRNP TUBB2B CSNK2A1 FOXP1 RFC2 TMCO1 GATA4 SNORD116-1 LIMK1 MED12 MYT1L CRBN SIX3 PTCHD1 ATP6V1A GLI2 SMPD1 ARV1 CRKL PMS1 SZT2 MCTP2 BPTF SIN3A SYP CDON ZMIZ1 TBX1 ZNF41 STEEP1 IQSEC2 CACNA1B CIC GABRB3 ACTL6A DEAF1 ZIC2 PSMD12 SCN8A MLH1 GABRA1 FOXH1 USP27X FGD1 TSC2 PHIP GRIN2D FGF8 SNRPN NDP NBN PRKCG TANC2 TGIF1 NLGN1 WAC UBE3A ZMIZ1 SMC1A HDAC4 TDGF1 TSC1 HMGA2 PTCH1 IQSEC1 GLI2 SEMA4A GAS1 PPP3CA GAS1 DOCK3 UFD1 TGIF1 SH3KBP1 PLAG1 GTF2I KDM3B GNAQ CYFIP2 KCNA2 KANSL1 GRIN2A PTCH1 NR2F1 TRAK1 UBA5 SETD5 TDGF1 RAI1 MED12L PARS2 TGIF1 BMPR1A CHD7 ARF1 UPF3B ALKBH8 SMC1A CDH2 NDN SETD2 UPF3B OCRL DHDDS HCFC1 SMC3 TDGF1 ZDHHC9 DLL1 TRMT1 SHH DPH1 SIX3 RERE TKT HDAC8 MLH3 HERC2 SRPX2 STAG2 DLG3 DRD5 MLXIPL MAP1B IQSEC2 BCR RSRC1 SETBP1 SPG7 SCN3A LHCGR BCORL1 NODAL BAZ1B DLL1 TRAPPC4 MED12 COMT USP7 DRD4 FLII NTNG1 ARHGEF6 DYNC1I2 NODAL RPS6KA3 AUTS2 RLIM TRIO PAH DISP1
    Protein Mutations 2
    D203E G143E

    Reports

    Data processed on December 13, 2020.

    An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.

    Drug Reports   MeSH Reports   HPO Reports  

    Interventions

    4,818 reports on interventions/drugs

    MeSH

    706 reports on MeSH terms

    HPO

    306 reports on HPO terms

    All Terms

    Alphabetical index of all Terms

    Google Colab

    Python example via Google Colab Notebook